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ABSTRACT
Objective To evaluate the cost-effectiveness of
implantable cardioverter deﬁbrillators (ICDs), cardiac
resynchronisation therapy pacemakers (CRT-Ps) and
combination therapy (CRT-D) in patients with heart
failure with reduced ejection fraction based on a range
of clinical characteristics.
Methods Individual patient data from 13 randomised
trials were used to inform a decision analytical model.
A series of regression equations were used to predict
baseline all-cause mortality, hospitalisation rates and
health-related quality of life and device-related treatment
effects. Clinical variables used in these equations were
age, QRS duration, New York Heart Association (NYHA)
class, ischaemic aetiology and left bundle branch block
(LBBB). A UK National Health Service perspective and a
lifetime time horizon were used. Beneﬁts were expressed
as quality-adjusted life-years (QALYs). Results were
reported for 24 subgroups based on LBBB status, QRS
duration and NYHA class.
Results At a threshold of £30 000 per QALY gained,
CRT-D was cost-effective in 10 of the 24 subgroups
including all LBBB morphology patients with NYHA I/II/
III. ICD is cost-effective for all non-NYHA IV patients
with QRS duration <120 ms and for NYHA I/II non-LBBB
morphology patients with QRS duration between 120 ms
and 149 ms. CRT-P was also cost-effective in all NYHA
III/IV patients with QRS duration >120 ms. Device
therapy is cost-effective in most patient groups with
LBBB at a threshold of £20 000 per QALY gained.
Results were robust to altering key model parameters.
Conclusions At a threshold of £30 000 per QALY
gained, CRT-D is cost-effective in a far wider group than
previously recommended in the UK. In some subgroups
ICD and CRT-P remain the cost-effective choice.
INTRODUCTION
In addition to guideline directed medical therapy,
implantable cardiac devices have an established
role in the treatment of heart failure with reduced
ejection fraction (HFrEF). International clinical
guidelines1–3 make recommendations for implanta-
ble cardioverter deﬁbrillators (ICDs), cardiac resyn-
chronisation therapy pacemakers (CRT-P) and the
combined device, CRT-D, based on the presence of
speciﬁc patient characteristics, recognising that the
extent of clinical beneﬁt associated with these
devices varies across subgroups within the broader
population of patients with HRrEF.
Healthcare systems internationally are seeking
evidence on the value for money of medical inter-
ventions, and ICD and CRT have been the subject
of a number of economic evaluations4–9 and health
technology assessments (HTAs).10–12 In general, the
conclusion has been that ICD and CRT are cost-
effective when compared with medical therapy, and
that CRT-D is marginally cost-effective when com-
pared with stand-alone CRT-P.
Clinical guidelines on ICD/CRT in HF make
recommendations based on a range of clinical para-
meters. These include New York Heart Association
(NYHA) class, left ventricular ejection fraction
(LVEF), ischaemic aetiology status, QRS duration,
and presence or absence of either atrial ﬁbrillation
or left bundle branch block (LBBB).2 3 Guidance
issued by HTA organisations such as the National
Institute for Health and Care Excellence
(NICE)13 14 is based on a subset of these para-
meters. The great majority of published ICD/CRT
economic evaluations, however, including those
informing NICE decisions, have been based on
data or populations from single clinical trials.
These analyses do not, therefore, reﬂect the totality
of randomised controlled trial evidence available,
and have only limited information with which to
explore the potential for cost-effectiveness (and
decisions based on cost-effectiveness) to vary by
patient subgroups.
This paper reports a unique collaboration
between manufacturers, clinicians and health econo-
mists to pool individual patient data from all major
randomised controlled trials of these devices
(N=12 638). This database of studies has been used
to inform a range of research studies.15 16 We
report its use to develop a cost-effectiveness analysis
for submission to NICE as part of their comprehen-
sive review of ICD and CRT designed to answer the
question ‘in which patients are ICD/CRT-P/CRT-D
cost-effective?’.16 Unlike previous studies, the ana-
lysis is based on a synthesis of evidence across trials
and reﬂects important differences between sub-
groups, hence guiding health systems’ resource allo-
cation decisions regarding these devices.
METHODS
Decision analytical modelling
The analysis is based on a typical UK HFrEF
patient population, starting age of 66 years, all
NYHA classes and LVEF ≤35%. The cost-
effectiveness analysis follows the methods
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recommended by NICE.17 Costs considered are those of the UK
National Health Service (NHS), and outcomes are expressed as
quality-adjusted life-years (QALYs). An annual discount rate of
3.5% is applied to both costs and beneﬁts.17
The analysis is based on a decision analytical model which
comprises a series of regression equations to predict: mortality,
hospitalisation rates and health-related quality of life (HRQoL).
The regression equations include covariables representing
patients’ baseline prognostic characteristics. The ﬁrst regression
equation predicts the probability of death in patients who only
receive medical therapy. This is combined with estimates of the
treatment effects of ICD, CRT-P and CRT-D based on the
results of a network meta-analyses15 to derive device-speciﬁc
mortality probabilities. A second equation is used to predict the
monthly probability of experiencing a hospitalisation event for
any reason. A ﬁnal equation estimates a patient’s HRQoL given
their characteristics and treatment. All living patients potentially
incur other costs related to device implant and replacement,
background medication and routine clinical visits.
Cost-effectiveness results are generated in a two-stage process.
In the ﬁrst stage, costs and QALYs are estimated for all interven-
tions for all possible sets of patient characteristics (‘patient pro-
ﬁles’). In the second, these are collapsed to 24 subgroups
deﬁned by NYHA class, QRS duration and presence or absence
of LBBB. Due to clinical contraindications or a paucity of evi-
dence, not all treatments are evaluated for each of the 24 sub-
groups (see online supplementary appendix 1, for details).
Expected (mean) costs and QALYs are estimated for all rele-
vant treatments in each subgroup, and the following standard
‘decision rules’ are followed to identify the cost-effective inter-
vention in each subgroup.18 First, any option that is less effect-
ive and more costly than one or more others is removed from
consideration (dominated). Second, the extra cost per additional
QALY (the incremental cost-effectiveness ratio (ICER)) of a
more effective treatment is calculated and any treatment that is
less effective than another with a higher ICER is removed from
consideration (extended dominance). The remaining options lie
on a cost-effectiveness ‘frontier’ which runs from least to most
costly/effective. ICERs are calculated between each progressively
more costly and effective option.
Estimating model inputs
The baseline mortality risk (patients receiving medical therapy
alone) was estimated using relevant individual patient data from
the included trials.15 Parametrical survival analysis was used to
extrapolate these mortality risks beyond the follow-up periods
in the trials in order to generate lifetime estimates. The follow-
ing candidate baseline covariables were selected based on
data availability, a review of risk scores, clinical guidelines,
randomised controlled trial (RCT) subgroup analyses and clinical
advice: age, QRS duration, LVEF, gender, NYHA class, ischaemic
aetiology, LBBB status and a binary geographical indicator to
track whether or not patients were from a North American
centre. Final covariable selection in all regression models was via
a stepwise procedure unless otherwise stated. Estimation of the
treatment effects of the devices on all-cause mortality has been
detailed elsewhere.15 Mortality treatment effects were assumed to
be maintained for 7.5 years (the maximum follow-up period in
the trials) after which they would decline so that, by 20 years,
there was no impact on mortality.
The expected number of all-cause hospitalisations per month
for patients on medical therapy, together with the treatment
effects of the devices, was estimated from the 11 trials reporting
relevant data (full list of studies reported in online
supplementary appendix 2). Hospitalisation rates were assumed
constant over a patient’s lifetime. Excluding LBBB morphology,
the covariates of interest were as for all-cause mortality. NYHA
I–II patients were considered together due to paucity of data on
NYHA I patients. For the analysis of the effect of devices on
hospitalisation rates, study-speciﬁc intercepts were included as
well as device-related main effects with interaction terms used
to identify treatment effect modiﬁers.
HRQoL estimates expressed on a 0 (equivalent of dead) to 1
(equivalent of good health) scale are necessary to quality-adjust
survival and calculate QALYs.18 Baseline HRQoL conditional
upon patients’ characteristics was estimated using data from the
three trials reporting EuroQol-5Dimension (EQ-5D) data (relevant
studies listed in online supplementary appendix 2). The treatment
effects of devices are estimated as the change from baseline (to ﬁrst
follow-up) in the treatment arms of the included trials, minus the
change from baseline in patients allocated to medical therapy. This
HRQoL treatment effect is assumed to be maintained for 5 years
based on information in the CArdiac REsynchronization — Heart
Failure (CARE-HF) trial,19 and then to decline to 0 by 10 years.
Throughout the model, a decline in HRQoL is applied to reﬂect
ageing, estimated using UK general population data.20
Hospitalisation costs are based on information on hospitalisa-
tion type from a UK-based population study.21 The typical HF
medications for each NYHA class are estimated based on a review
of the clinical literature and expert opinion. With the exception of
those relating to device systems, all costs are taken from national
databases.22–24 The total implant cost for CRT-P is based on a rele-
vant Healthcare Resource Group code. For CRT-D and ICD, no
such codes exist, so cross-manufacturer average selling prices for
both systems and leads were made available by the Association of
British Healthcare Industries for the purpose of this analysis (see
online supplementary appendix 3).
Device longevity estimates are based on data from the Central
Cardiac Audit Database. Parametrical survival models are used
to model time to ﬁrst and subsequent device replacements (see
online supplementary appendix 3).
A range of sensitivity and scenario analyses are undertaken to
quantify the importance of the key modelling assumptions. Of
particular importance is the uncertainty in assumptions regard-
ing the duration of the mortality and HRQoL treatment effects.
Alternative values explored as sensitivity analyses were: (1) a
constant, lifetime mortality effect (as in previous UK reimburse-
ment models10 12); (2) a 5 year time period; and (3) the mean
follow-up period from the studies included in the data analyses
(2.54 years). A sensitivity analysis was also conducted using life-
time treatment effect durations for both all-cause mortality and
HRQoL (as per previous UK reimbursement models). Further
sensitivity analyses were undertaken including varying key costs,
increasing device longevity, the use of an alternative approach to
modelling all-cause hospitalisation and the use of NYHA class as
a modiﬁer of all-cause mortality treatment effect.
Software
All mortality related analyses were performed in R (http://www.
r-project.org), with all analysis of hospitalisation and HRQoL
performed in STATA V.12 (StataCorp. College Station, Texas,
USA). The economic model was developed in Microsoft Excel
(Microsoft, Redmond, Washington DC, USA).
RESULTS
All-cause mortality
Full details of the mortality model are reported in the supple-
mentary appendix 4. The risk of death was higher in patients
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who are older, male or with ischaemic aetiology. The risk of
death was also found to increase across NYHA classes, and was
more than three times higher in individuals in NYHA Class IV
than those in NYHA I/II. The risk of mortality was lower in
patients with a normal (<120 ms) versus longer QRS duration
(HR=0.84) and decreased as LVEF increased. Long-term sur-
vival predictions for each subgroup and treatment are presented
in the supplementary appendix 5. Allowing for variations in
within-group sample size and covariate mix the results are
broadly internally consistent and in line with the published
literature.
All-cause hospitalisation
Full details of the baseline hospitalisation model are reported in
the supplementary appendix 4. Patients in NYHA Classes III
and IV were 2.1 times and 4.4 times, respectively, more likely to
be hospitalised than those in NYHA Class I/II. Ischaemic aeti-
ology increased the rate of hospitalisation by 9% and wide QRS
complex increased the rate by 22% (120–149 ms) and 6%
(150 ms or more), respectively.
The model predicted that ICDs reduced monthly hospitalisa-
tion rates by 20% in patients with NYHA I/II/III HF. CRT-P was
associated with reductions in monthly hospitalisation rates of
32% and 40%, respectively, in patients with NYHA III/IV HF.
CRT-D was associated with a monthly rate reduction of 30% in
patients with NYHA I–IV HF. In NYHA III/IV patients the treat-
ment effects arising from the patient level data for CRT-D com-
pared with those generated for CRT-P were considered clinically
implausible. For the base case analysis of these patients we
therefore assumed equivalence of efﬁcacy for CRT-D and
CRT-P. Subgroup/treatment-speciﬁc lifetime hospitalisation counts
are reported in supplementary appendix 5. These data require
careful interpretation since subgroups with longer overall survival
have more hospitalisation events.
Health-related quality of life
Full details of the HRQoL model are reported in the supple-
mentary appendix 4. Statistically signiﬁcant (p<0.05) but
modest improvements from baseline were observed for ICD and
CRT-D in patients with NYHA I or II heart failure, and CRT-P
in NYHA Class III (+0.02, +0.03 and +0.091, respectively).
No signiﬁcant impact was observed on HRQoL with ICD or
CRT-D therapy in patients in NYHA Class III. Meaningful
results for patients with NYHA IV HF could not be generated
due to the very low numbers of patients in the clinical trials.
For the purposes of economic modelling, equivalence of
HRQoL beneﬁt for CRT-P and CRT-D was again assumed in
NYHA III and IV HF. This assumption can be justiﬁed on the
basis of a review of external sources and trial-speciﬁc Minnesota
Living with Heart Failure data.16
Cost-effectiveness—base case
The base case results for all subgroups are presented in table 1.
For each patient subgroup, the order of treatments on the cost-
effectiveness frontier is shown, and the ICERs for each option
which is not subject to dominance or extended dominance.
Table 2 shows the cost-effective option for each subgroup (cost-
effectiveness threshold: £30 000 per QALY gained). Device
therapy is cost-effective at this threshold in all subgroups exam-
ined. CRT-D is cost-effective in 10 of the 24 subgroups, and is
Table 1 Base case results. Cost-effectiveness sequence relates to the order in which interventions appear on the cost-effectiveness frontier
Cost-effectiveness sequence Incremental cost-effective ratios
Patient group 1st 2nd 3rd 4th 1st 2nd 3rd 4th
Individuals without LBBB morphology
NYHA I, QRS duration <120 ms* MT ICD N/A N/A Referent £24 074 N/A N/A
NYHA I, QRS duration ≥120 ms and <150 ms* MT CRT-D ICD N/A Referent Dominated £16 253 N/A
NYHA I, QRS duration ≥150 ms* MT ICD CRT-D N/A Referent £21 102 £21 759 N/A
NYHA II, QRS duration <120 ms MT ICD N/A N/A Referent £24 465 N/A N/A
NYHA II, QRS duration ≥120 ms and <150 ms MT CRT-D ICD N/A Referent Dominated £16 813 N/A
NYHA II, QRS duration ≥150 ms MT ICD CRT-D N/A Referent £20 602 £23 738 N/A
NYHA III, QRS duration <120 ms MT ICD N/A N/A Referent £27 826 N/A N/A
NYHA III, QRS duration≥120 ms and <150 ms MT CRT-P ICD CRT-D Referent £20 178 Ext Dominated £23 349
NYHA III, QRS duration ≥150 ms MT ICD CRT-P CRT-D Referent Dominated £13 930 £25 200
NYHA IV, QRS duration <120 ms MT N/A N/A N/A Referent N/A N/A N/A
NYHA IV, QRS duration ≥120 ms and <150 ms MT CRT-P CRT-D N/A Referent £22 578 £40 052 N/A
NYHA IV, QRS duration ≥150 ms MT CRT-P CRT-D N/A Referent £17 175 £35 811 N/A
Individuals with LBBB morphology
NYHA I, QRS duration ≥120 ms and <150 ms* MT ICD CRT-D N/A Referent £20 677 £21 672 N/A
NYHA I, QRS duration ≥150 ms* MT ICD CRT-D N/A Referent Ext Dominated £17 470 N/A
NYHA II, QRS duration ≥120 ms and <150 ms MT ICD CRT-D N/A Referent Ext Dominated £20 704 N/A
NYHA II, QRS duration ≥150 ms MT ICD CRT-D N/A Referent Ext Dominated £17 664 N/A
NYHA III, QRS duration ≥120 ms and <150 ms MT ICD CRT-P CRT-D Referent Dominated £14 215 £24 875
NYHA III, QRS duration ≥150 ms MT ICD CRT-P CRT-D Referent Dominated £10 496 £28 646
NYHA IV, QRS duration ≥120 ms and <150 ms MT CRT-P CRT-D N/A Referent £18 664 £37 104 N/A
NYHA IV, QRS duration ≥150 ms MT CRT-P CRT-D N/A Referent £14 500 £40 449 N/A
‘N/A’ represents fewer than four interventions being considered. Options labelled as ‘Dominated’ or ‘Ext Dominated’ do not lie on the frontier.
*Results in NYHA I and IV patients are based on relatively low patient numbers and may be subject to bias due to the nature of trial inclusion criteria for NYHA I patients. For further
detail see main text.
CRT, cardiac resynchronisation therapy; CRT-D, combined CRT and ICD device; CRT-P, stand-alone CRT device; ICD, implantable cardioverter defibrillator; LBBB, left bundle branch block;
MT, medical therapy; N/A, not applicable; NYHA, New York Heart Association.
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cost-effective for all LBBB morphology patients with NYHA
I/II/III. ICDs are cost-effective for all non-NYHA IV patients
with a QRS duration <120 ms and for NYHA I/II, non-LBBB
morphology patients with a QRS duration between 120 ms and
149 ms. CRT-P is cost-effective for all NYHA IV patients
evaluated.
Results generated using a more stringent threshold value
(£20 000 per QALY gained) are presented in table 3. CRT-D is
only cost-effective in two patient groups (NYHA I or II, QRS
duration ≥150 ms, with LBBB); ICD is only cost-effective in
two patient groups (NYHA I or II, QRS duration between 120
ms and 149 ms, no LBBB); and CRT-P is cost-effective in six
patient groups (NYHA III or IV, QRS duration >120 ms, and
LBBB and also NYHA III/IV, QRS duration ≥150 ms and no
LBBB).
The nature of the cost-effective intervention is dependent
upon the cost-effectiveness threshold (ﬁgure 1). Beyond a
threshold value of approximately £24 500 per QALY gained, for
patients without LBBB morphology, the treatments identiﬁed in
the base case analysis are largely robust to changes in threshold.
For patients with LBBB morphology there is generally less sensi-
tivity to changes in threshold, with the cost-effective treatments
presented in table 2 largely unchanged beyond a threshold value
of approximately £22 000 per QALY.
Results in NYHA I and IV patients are subject to additional
uncertainty due to the numbers of patients informing these ana-
lyses and the nature of the trial inclusion criteria for NYHA I
patients, these issues are described in the discussion.
Sensitivity analyses
The choice of cost-effective therapy was, in general, unchanged
when varying the duration of maximum all-cause mortality
treatment effect (table 4, threshold value £30 000 per QALY
gained). A similar outcome was noted when the assumption of
lifetime treatment effect durations for both all-cause mortality
and HRQoL improvements was made (table 4). A detailed
breakdown of the fully incremental ICERs generated in this
latter analysis is presented in the supplementary appendix 6.
The corresponding results generated using a threshold value of
£20 000 per QALY gained are presented in table 5.
The impact of varying key costs, increasing device longevity,
the use of an alternative approach to modelling all-cause hospi-
talisation and the use of NYHA class as an all-cause mortality
treatment effect modiﬁer on the choice of devices at thresholds
of £20 000 and £30 000 per QALY gained was modest. Hence,
the model was robust to changes in these parameters.
DISCUSSION
The clinical efﬁcacy of CRT and ICD therapy has been investi-
gated in numerous studies, and these technologies are estab-
lished therapies for HFrEF individuals in international practice.
The uniqueness of the database created for the purpose of this
analysis lies in the ability to explore the clinical efﬁcacy of CRT
and ICD in detail, and in particular to pursue a thorough inves-
tigation of the impact of key clinical variables on both the base-
line risk of death and the efﬁcacy of each treatment option in
reducing mortality.15 The database also facilitated the incorpor-
ation of clinical subgroups into the cost-effectiveness assessment
so the devices representing best value for money for patients
with different sets of clinical characteristics could be identiﬁed.
This collaboration can serve as a model for similar collabor-
ation across manufacturers. Pooling together clinical data across
manufactures can help manufactures, physicians and policy
makers become more conﬁdent in the clinical-effectiveness and
cost-effectiveness of a therapy and get a better understanding of
how this varies across patients.
The analysis presented here was used to inform the recent
NICE guidance regarding the use of these technologies. The
committee developing the NICE recommendations recognised
this analysis as ‘a rich and important data source’,25 and based
its decision making on it. The guidance issued by NICE in 2014
reﬂected the ﬁndings of this cost-effectiveness analysis in almost
all subgroups,25 with the exception of CRT-D in patients with
NYHA III and QRS 120–149 ms without LBBB morphology
and CRT-D in asymptomatic (NYHA Class I) patients with QRS
120–149 ms. ICD was recommended in both cases due to con-
cerns about reduced effectiveness and a lack of symptomatic
beneﬁt of CRT in these subgroups.
Table 2 Summary of cost-effectiveness recommendations arising
from the base case analysis (threshold value: £30 000 per QALY
gained)
NYHA
QRS duration
<120 ms
QRS duration
120–150 ms
QRS duration
>150 ms
Patients without LBBB morphology
I* ICD ICD CRT-D
II ICD ICD CRT-D
III ICD CRT-P/CRT-D† CRT-P/CRT-D†
IV Medical therapy CRT-P CRT-P
Patients with LBBB morphology
I* CRT-D CRT-D
II CRT-D CRT-D
III CRT-P/CRT-D† CRT-P/CRT-D†
IV CRT-P CRT-P
*Results in NYHA I and IV patients are based on relatively low patient numbers and
may be subject to bias due to the nature of trial inclusion criteria for NYHA I
patients. For further detail see main text.
†Instances where NICE recommended two devices based on fully incremental results
and a threshold of £30 000 per QALY gained. CRT-P values are relative to medical
therapy and CRT-D values relative to CRT-P.
CRT, cardiac resynchronisation therapy; CRT-D, combined CRT and ICD device; CRT-P,
stand-alone CRT device; ICD, implantable cardioverter defibrillator; LBBB, left bundle
branch block; NICE, National Institute for Health and Care Excellence; NYHA,
New York Heart Association; QALY, quality-adjusted life-year.
Table 3 Summary of cost-effectiveness recommendations arising
from the base case analysis (threshold value: £20 000 per QALY
gained)
NYHA
QRS duration
<120 ms
QRS duration
120–150 ms
QRS duration
>150 ms
Patients without LBBB morphology
I* Medical therapy ICD Medical therapy
I Medical therapy ICD Medical therapy
III Medical therapy Medical therapy CRT-P
IV Medical therapy Medical therapy CRT-P
Patients with LBBB morphology
I* Medical therapy CRT-D
II Medical therapy CRT-D
III CRT-P CRT-P
IV CRT-P CRT-P
*Results in NYHA I and IV patients are based on relatively low patient numbers and
may be subject to bias due to the nature of trial inclusion criteria for NYHA I
patients. For further detail see main text.
CRT, cardiac resynchronisation therapy; CRT-D, combined CRT and ICD device; CRT-P,
stand-alone CRT device; ICD, implantable cardioverter defibrillator; LBBB, left bundle
branch block; NYHA, New York Heart Association; QALY, quality-adjusted life-year.
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The major source of uncertainty identiﬁed during the NICE
appraisal of these technologies was the duration of treatment
effect on all-cause mortality. The duration of effect used in this
analysis (7.5 years) is supported by a number of long-term
studies. Recently published data from the CARE-HF study19
found that, at a mean follow-up of 56 months in the CRT-P and
50 months in the medical therapy arms, the HR for all-cause
mortality (CRT-P vs optimal pharmacological therapy (OPT))
was 0.77 (95% CI 0.63 to 0.93), despite 39% of control
patients crossing over to a CRT device during follow-up. In add-
ition, long-term follow-up from the Multicenter Automatic
Deﬁbrillator Implantation Trial-II (MADIT-II) study26 found
that, at a median follow-up of 7.6 years, the HR for all-cause
mortality (ICD vs non-ICD) was 0.77 (0.65 to 0.91), although
34% of control patients crossed over to a device during
follow-up. Attempts to adjust statistically for cross-over resulted
in treatment effect estimates of 0.67 (0.56 to 0.80) and 0.66
(0.56 to 0.78), in CARE-HF and MADIT-II, respectively.19 26
The results from our analysis, generated using a cost-
effectiveness threshold of £30 000 per QALY gained, broadly
agrees with guidelines issued by the European Society of
Cardiology.3 27 In patients with QRS<120 ms, NYHA II–III and
ejection fraction (EF)≤35%, ICD is recommended and cost-
effective according to our analysis. In ambulatory NYHA IV
patients with prolonged QRS duration, CRT-P is recommended
and cost-effective. Our analysis provides information on where
scarce resources should be targeted in patients with QRS pro-
longation and in NYHA Class II or III where several possible
device options are recommended. In particular, it suggests that
CRT-D is cost-effective in NYHA II–III patients with LBBB
morphology, and that, in patients with non-LBBB morphology,
CRT-D is cost-effective in all groups with the exception of NYHA
II patients with a QRS duration of 120–149 ms. Unlike previous
guidelines, the current analysis suggests implantable devices may
be cost-effective in asymptomatic patients (NYHA Class I).
However, given the small number of patients in these groups in
the trials, results in NYHA Class I, and in particular in relation to
CRT-D in this patient group, should be regarded with caution.15
Comparison of the results from the current analysis with pre-
vious UK Health Technology Assessment (HTA) models of ICD
Figure 1 Graphic display of cost-effective options across cost-effectiveness threshold values (base case). CRT, cardiac resynchronisation therapy;
CRT-D, combined CRT and ICD device; CRT-P, stand-alone CRT device; ICD, implantable cardioverter deﬁbrillator; LBBB, left bundle branch block;
NYHA, New York Heart Association; QALY, quality-adjusted life-year.
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Table 4 Impact of duration of treatment effect on treatment choice (threshold £30 000 per QALY gained)
Subgroup
Duration of mortality treatment effect Lifetime mortality
and constant HRQoLLifetime 7.5 years 5 years Mean f/up
Individuals without LBBB
NYHA I, QRS <120 ms* ICD ICD ICD ICD ICD
NYHA I, QRS ≥120 ms and <150 ms* ICD ICD ICD ICD ICD
NYHA I, QRS ≥150 ms* CRT-D CRT-D CRT-D CRT-D CRT-D
NYHA II, QRS <120 ms ICD ICD ICD ICD ICD
NYHA II, QRS ≥120 ms and <150 ms ICD ICD ICD ICD ICD
NYHA II, QRS ≥150 ms CRT-D CRT-D CRT-D CRT-D CRT-D
NYHA III, QRS <120 ms ICD ICD ICD MT ICD
NYHA III, QRS ≥120 ms and <150 ms CRT-D CRT-D CRT-D CRT-D CRT-D
NYHA III, QRS ≥150 ms CRT-D CRT-D CRT-D CRT-D CRT-D
NYHA IV, QRS <120 ms MT MT MT MT MT
NYHA IV, QRS ≥120 ms and <150 ms CRT-P CRT-P CRT-P CRT-P CRT-P
NYHA IV, QRS ≥150 ms CRT-P CRT-P CRT-P CRT-P CRT-P
Individuals with LBBB
NYHA I, QRS ≥120 ms and <150 ms* CRT-D CRT-D CRT-D CRT-D CRT-D
NYHA I, QRS ≥150 ms* CRT-D CRT-D CRT-D CRT-D CRT-D
NYHA II, QRS ≥120 ms and <150 ms CRT-D CRT-D CRT-D CRT-D CRT-D
NYHA II, QRS ≥150 ms CRT-D CRT-D CRT-D CRT-D CRT-D
NYHA III, QRS ≥120 ms and <150 ms CRT-D CRT-D CRT-D CRT-D CRT-D
NYHA III, QRS ≥150 ms CRT-D CRT-D CRT-P CRT-P CRT-D
NYHA IV, QRS ≥120 ms and <150 ms CRT-P CRT-P CRT-P CRT-P CRT-P
NYHA IV, QRS ≥150 ms CRT-P CRT-P CRT-P CRT-P CRT-P
Changes from base case highlighted in bold.
*Results in NYHA I and IV patients are based on relatively low patient numbers and may be subject to bias due to the nature of trial inclusion criteria for NYHA I patients. For further
detail see main text.
CRT, cardiac resynchronisation therapy; CRT-D, combined CRT and ICD device; CRT-P, stand-alone CRT device; HRQoL, health-related quality of life; ICD, implantable cardioverter
defibrillator; LBBB, left bundle branch block; MT, medical therapy; NYHA, New York Heart Association; QALY, quality-adjusted life-year.
Table 5 Impact of duration of treatment effect on treatment choice (threshold £20 000 per QALY gained)
Subgroup
Duration of mortality treatment effect Lifetime mortality
and constant HRQoLLifetime 7.5 years 5 years Mean f/up
Individuals without LBBB
NYHA I, QRS <120 ms* ICD MT MT MT ICD
NYHA I, QRS ≥120 ms and <150 ms* ICD ICD ICD ICD ICD
NYHA I, QRS ≥150 ms* CRT-D MT MT MT CRT-D
NYHA II, QRS <120 ms ICD MT MT MT ICD
NYHA II, QRS ≥120 ms and <150 ms ICD ICD ICD ICD ICD
NYHA II, QRS ≥150 ms CRT-D MT MT MT ICD
NYHA III, QRS <120 ms MT MT MT MT MT
NYHA III, QRS ≥120 ms and <150 ms CRT-P MT MT MT CRT-P
NYHA III, QRS ≥150 ms CRT-P CRT-P CRT-P CRT-P CRT-P
NYHA IV, QRS <120 ms MT MT MT MT MT
NYHA IV, QRS ≥120 ms and <150 ms MT MT MT MT MT
NYHA IV, QRS ≥150 ms CRT-P CRT-P CRT-P CRT-P CRT-P
Individuals with LBBB
NYHA I, QRS ≥120 ms and <150 ms* CRT-D MT MT MT CRT-D
NYHA I, QRS ≥150 ms* CRT-D CRT-D CRT-D MT CRT-D
NYHA II, QRS ≥120 ms and <150 ms CRT-D MT MT MT CRT-D
NYHA II, QRS ≥150 ms CRT-D CRT-D CRT-D MT CRT-D
NYHA III, QRS ≥120 ms and <150 ms CRT-P CRT-P CRT-P CRT-P CRT-P
NYHA III, QRS ≥150 ms CRT-P CRT-P CRT-P CRT-P CRT-P
NYHA IV, QRS ≥120 ms and <150 ms CRT-P CRT-P CRT-P CRT-P CRT-P
NYHA IV, QRS ≥150 ms CRT-P CRT-P CRT-P CRT-P CRT-P
Changes from base case highlighted in bold.
*Results in NYHA I and IV patients are based on relatively low patient numbers and may be subject to bias due to the nature of trial inclusion criteria for NYHA I patients. For further
detail see main text.
CRT, cardiac resynchronisation therapy; CRT-D, combined CRT and ICD device; CRT-P, stand-alone CRT device; HRQoL, health-related quality of life; ICD, implantable cardioverter
defibrillator; LBBB, left bundle branch block; MT, medical therapy; NYHA, New York Heart Association; QALY, quality-adjusted life-year.
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and CRT is challenging due to the different model structures
and evidence used. The earlier models used aggregate level evi-
dence, whereas the current model was based on access to a large
amount of individual patient data. Accepting these differences,
the results from the sensitivity analysis performed with the
removal of all tapering effects on treatment effect durations are
the most comparable with earlier models. This showed that the
ICERs from the current analysis are lower (ie, better value for
money) than those considered acceptable in previous NICE
guidance. The reasons for this are likely to be increases in
average device longevity and a reduction in hardware acquisition
costs. In many cases, where ICD was historically recommended,
the current analysis suggests patients should be offered a CRT-D
device as the most clinically effective and cost-effective option.
A number of limitations arose from the choice of modelling
approach and data on which the analyses were based, with the
main area of potential concern being that some of the patient
groups modelled were sparsely represented in our database. The
primary groups of concern relate to patients in NYHA Classes I
and IV heart failure (HF) (regardless of LBBB status).
Cost-effectiveness results in these groups may have been inﬂu-
enced by the small patient numbers and should be treated with
caution. In addition, NYHA I patients in trials may be atypical
of those observed in clinical practice as speciﬁc inclusion criteria
were used to focus on patients who were easily identiﬁable.28 29
Omitting previous HF hospitalisations as a predictor of subse-
quent monthly hospitalisation events represents a limitation of
our analysis. However, the total event rates predicted are low
and the choice of modelling approach is therefore unlikely to
have had a substantive impact on the model results.
In conclusion, from a UK NHS perspective, at a threshold of
£30 000 per QALY gained our analysis has shown that CRT-D is
cost-effective in a far wider group of patients than previously
recommended and that, for most other patients, ICD is a cost-
effective treatment alternative. Our analysis also showed that CRT-
P was cost-effective in all patients with NYHA III/IV and a QRS
duration >120 ms. Device therapy is cost-effective in most patient
groups with LBBB at a threshold of £20 000 per QALY gained.
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